KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Cash (2016 - 2025)

Historic Change in Cash for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$4.5 million.

  • Neogenomics' Change in Cash fell 18962.15% to -$4.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$207.4 million, marking a year-over-year decrease of 94567.77%. This contributed to the annual value of -$207.4 million for FY2025, which is 94567.77% down from last year.
  • As of Q4 2025, Neogenomics' Change in Cash stood at -$4.5 million, which was down 18962.15% from $9.4 million recorded in Q3 2025.
  • Neogenomics' 5-year Change in Cash high stood at $372.5 million for Q1 2021, and its period low was -$250.2 million during Q2 2021.
  • Moreover, its 5-year median value for Change in Cash was -$3.7 million (2022), whereas its average is -$4.6 million.
  • As far as peak fluctuations go, Neogenomics' Change in Cash soared by 133044.81% in 2023, and later crashed by 92633.9% in 2025.
  • Over the past 5 years, Neogenomics' Change in Cash (Quarter) stood at -$26.9 million in 2021, then surged by 89.05% to -$2.9 million in 2022, then soared by 1330.45% to $36.2 million in 2023, then crashed by 86.15% to $5.0 million in 2024, then tumbled by 189.62% to -$4.5 million in 2025.
  • Its Change in Cash stands at -$4.5 million for Q4 2025, versus $9.4 million for Q3 2025 and -$191.5 million for Q2 2025.